BRAFm+ Metastatic melanoma
What makes it different, makes it vulnerable

BRAFm+ metastatic melanoma
What makes it different makes it vulnerable

Information and advances in our understanding of melanoma continue to evolve. Approximately half of all cases of melanoma harbour a mutation in BRAF, making it the most common genetic subtype of cutaneous melanoma.1,2

Here you’ll find information about BRAF mutation and its role in melanoma, the rationale for BRAF-mutation testing and treatment with BRAF inhibitors, the procedures for BRAF-mutation testing, and the testing methods that are available.

 

Expert insights in BRAFm+ melanoma

A closer look into the development of BRAFm+ melanoma

Watch now!

 

Expert insights in BRAFm+ melanoma

Advances in screening for BRAF mutational advanced melanoma

Watch now!

  1. The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681-96.
  2. Jakob JA, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-23.